Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...
THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovariancancer and other solid tumours. Suitable ...